Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Q3 2023 Earnings Conference Call November 9, 2023 8:00 AM ET

Company Participants

Lindsey Allen - Head of Investor Relations & Communications

Josh Cohen - Co-CEO & Co-Founder

Justin Klee - Co-CEO & Co-Founder

Margaret Olinger - Chief Commercial Officer

James Frates - Chief Financial Officer

Conference Call Participants

Corinne Jenkins - Goldman Sachs

Geoff Meacham - Bank of America

Umer Raffat - Evercore ISI

Marc Goodman - Leerink Partners

Graig Suvannavejh - Mizuho Partners

Ananda Ghosh - H.C. Wainwright & Co.

Operator

Good morning. My name is Keith, and I will be your conference operator today. At this time, I would like to welcome everyone to the Amylyx Pharmaceuticals Third Quarter 2023 Earnings Conference Call. All participants will be in listen-only mode. [Operator Instructions]. Please be advised this call is being recorded at the company's request.

I would now like to turn the conference over to Lindsey Allen, Head of Investor Relations and Communications. Please proceed, ma'am.

Lindsey Allen

Good morning, and thank you for joining us today to discuss our third quarter 2023 earnings. With me on the call are Josh Cohen and Justin Klee, our Co-CEOs; Margaret Olinger, our Chief Commercial Officer; and Jim Frates, our Chief Financial Officer.

Before we begin, I would like to remind everyone that any statements we make or information presented on this call that are not historical facts are forward-looking statements that are made based on our current beliefs, plans and expectations and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, our expectations with respect to RELYVRIO and ALBRIOZA, statements regarding our current and planned clinical trials and regulatory developments and the expected timing thereof, our business and marketing strategy and outlook and our expected financial performance.

Actual events and results could differ materially from those expressed or implied by any forward-looking statements as a result of various risks, uncertainties and other factors, including those set forth in our most recent filings with the SEC and any other future filings that we may make with the SEC. You are cautioned not to place any undue reliance on these forward-looking statements, and Amylyx disclaims any obligation to update such statements unless required by law.

Now I will turn the call over to Justin.

Justin Klee

Thank you, Lindsey, and good morning. As we sit here three full quarters into our U.S. launch in ALS, we are proud of what we have accomplished. We are also keenly focused on the work we still need to do to help transform and improve the way that ALS is treated. Our progress with RELYVRIO continues.